Board approves allotment of 34,00,000 equity shares on conversion of warrants to two non-promoter investors
Hemo Organic's Board approved allotment of 34,00,000 fully paid-up equity shares on conversion of 34,00,000 warrants.
By ScoutQuest · · 1 min read
- Warrants Converted
- 34,00,000 fully paid-up equity shares on conversion of 34,00,000 warrants
- Issue Price
- Rs. 12.50 per share (face value Rs. 10.00 + premium Rs. 2.50)
- Cash Received
- Balance 75% of Rs. 9.375 each, aggregating Rs. 3,18,75,000
- Non-Promoter Allottees
- Vacro Enterprises Pvt Ltd and Qmin Realities Pvt Ltd — 17,00,000 shares each, 24.76% each
- Paid-up Capital Increase
- From 34,65,900 shares to 68,65,900 shares
What happened
The Board, at its meeting on 25th September 2026 (05:00 P.M. to 05:30 P.M.), approved allotment of 34,00,000 fully paid-up equity shares on conversion of 34,00,000 convertible warrants issued on a preferential basis.
Pricing and money received
- Face value: Rs. 10.00 per share; premium Rs. 2.50; issue price Rs. 12.50 per share.
- The warrant holders had paid 25% upfront, totalling Rs. 1,06,25,000.
- Balance 75% of Rs. 9.375 each has now been received, aggregating Rs. 3,18,75,000, in tranches of Rs. 2,76,25,000 and Rs. 42,50,000.
Who got the shares
- Vacro Enterprises Private Limited (Non-Promoter): 17,00,000 shares, 24.76% post-issue.
- Qmin Realities Private Limited (Non-Promoter): 17,00,000 shares, 24.76% post-issue.
Both held nil shares before this allotment.
Effect on share capital
Existing paid-up capital was 34,65,900 shares (Rs. 3,46,59,000). After the allotment it stands at 68,65,900 shares. The share count roughly doubles, so existing shareholders' proportionate holding is diluted, while the company receives cash.
Next step
The new shares rank pari-passu with existing equity shares. The company will apply to the stock exchange for listing and trading of these shares in due course.
How to read this
Warrant conversion brings fresh funds into the company and adds two substantial non-promoter shareholders. The trade-off for existing investors is dilution, since per-share metrics are now spread over a larger share base.
Also from Hemo Organic
Standalone results for the quarter ended 30.09.2026 (Unaudited)
17 Oct 2026
Board approves unaudited Q2 and half-year results; auditor's review carries a qualified opinion
17 Oct 2026
Board meeting on 17 October 2026 to consider un-audited results for the quarter and half year ended 30 September 2026
14 Oct 2026
More numbers
- Equity shares allotted34,00,000
- Warrants converted34,00,000 convertible warrants
- Face value per shareRs. 10.00/-
- Issue price per shareRs. 12.50/-
- Premium per shareRs. 2.50/-
- Balance exercise price per warrantRs. 9.375/-
- Balance amount receivedRs. 3,18,75,000/-
- First trancheRs. 2,76,25,000
- Second tranche42,50,000
- Upfront 25% consideration received1,06,25,000
- Existing paid-up equity shares34,65,900
- Post-allotment equity shares68,65,900
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.